Swiss biotechnology company Araris Biotech completed its sale to Taiho Pharmaceutical. In connection with the deal BGPartner advised Araris on all Swiss legal matters, while Baker McKenzie represented the company with regard to all Swiss tax aspects. The context A spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich, Araris Biotech developes next-generation […]
Niederer Kraft Frey (NKF) advised AB2 Bio, a Swiss biotechnology company, on Swiss law matters in connection with the entry into an option and licensing agreement with Japanese pharmaceutical company Nippon Shinyaku. The context Headquartered
Walder Wyss advised Danish life science investor Novo Holdings through its acquisition of American pharma multinational Catalent. Globally active in the fields of life sciences and healthcare, Novo Holdings acts as the only asset manager
Vischer advised Atanis Biotech, a Swiss biotechnology company, to successful completion of an oversubscribed financing round. The financing round The proceeds from this operation will fund the European and North-American marketing campaigns for Atanis’s “
Vischer advised Chinese companies Kelun-Biotech and Harbour BioMed in all Swiss law matters of a licencing agreement. Moreover, the Swiss law firm assisted RTW, an investor, within the seed financing round of Winward Bio, the
ATANIS Biotech, a Swiss biotechnology company specializing in functional allergy diagnosis, announced the successful completion of a significant capital increase. iXLife, a French venture capital fund, co-led the round with US-based AllerFund, the first and
Kellerhals Carrard has reorganised and strengthened its Life Sciences team. It is now fully integrated into the value chain of its clients in the pharmaceutical, medical technology, health and nutrition sectors and is led by
Wenger Vieli advised TriNetX, a portfolio company of Carlyle, on its acquisition of Clinerion, a Swiss-based subsidiary of Norstella. Through a new multi-faceted, long-term agreement Norstella with Clinerion and TriNetX expand the world’s leading
Oculis Holding, a global biopharmaceutical company, purposefully driven to save sight and improve eye care, listed its shares on Nasdaq after successfully closing the business combination between European Biotech Acquisition Corp. (“EBAC”). At closing, Oculis
Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system disorders, successfully closed an oversubscribed Series B financing round, raising CHF 103 mio (approx. USD 112 mio). The round was co-led by the European healthcare focused
